Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of anti-Xa trough monitoring during therapeutic nadroparin treatment
NL-OMON49087Active, not recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Aug 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of nadroparin in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (2 cohorts), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Mean anti-Xa trough and peak levels per subgroup. Started Aug 2020; status: active, not recruiting.
02
Drugs
nadroparin
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON49087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49087.